Outlook Therapeutics マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Bob Jahr

最高経営責任者

US$1.7m

報酬総額

CEO給与比率	8.61%
CEO在任期間	1.1yrs
CEOの所有権	n/a
経営陣の平均在職期間	3.6yrs
取締役会の平均在任期間	8yrs

経営陣の近況

Recent updates

CEO報酬分析

Outlook Therapeutics の収益と比較して、Bob Jahr の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2026	n/a	n/a	-US$61m
Mar 31 2026	n/a	n/a	-US$61m
Dec 31 2025	n/a	n/a	-US$103m
Sep 30 2025	US$2m	US$150k	-US$62m

報酬と市場: Bobの総報酬 ($USD 1.74M ) は、 German市場 ($USD 397.27K ) の同規模の企業の平均を上回っています。

報酬と収益: Bobの報酬と会社の業績を比較するにはデータが不十分です。

CEO

Bob Jahr (53 yo)

1.1yrs

在職期間

US$1,741,757

報酬

Mr. Robert Charles Jahr, also known as Bob, is President, Chief Executive Officer & Director of Outlook Therapeutics, Inc. from July 1, 2025. From September 2018 to April 2020, he served as Vice President...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Jahr	President	1.1yrs	US$1.74m	データなし
Lawrence Kenyon	EVP, CFO	10.9yrs	US$476.17k	0.0032% € 3.9k
Joel Prieve	Senior Vice President of Licensing and M&A	4.5yrs	データなし	データなし
Surendra Sharma	Senior Vice President of Medical Affairs	3.6yrs	データなし	データなし
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	データなし	データなし
Jedd Comiskey	Senior VP - Head of Europe	2.8yrs	データなし	データなし

3.6yrs

平均在職期間

経験豊富な経営陣: 41Oの経営陣は経験豊富であると考えられます ( 3.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Jahr	President	1.1yrs	US$1.74m	データなし
Lawrence Kenyon	EVP, CFO	8yrs	US$476.17k	0.0032% € 3.9k
Kurt Hilzinger	Independent Director	10.7yrs	US$842.00k	0.23% € 276.8k
Ralph Thurman	Lead Independent Director	8.3yrs	US$836.50k	0.0030% € 3.7k
Julian Gangolli	Independent Non-Employee Director	6.3yrs	US$690.50k	0% € 0
Gerd Auffarth	Independent Non-Employee Director	6.3yrs	US$458.00k	0% € 0
Faisal Sukhtian	Independent Chairman of the Board	8.9yrs	US$1.00m	0.12% € 144.4k
Yezan Haddadin	Independent Director	8.8yrs	US$974.00k	0.035% € 43.2k
Andong Huang	Independent Director	6.2yrs	US$425.00k	0% € 0

8.0yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: 41Oの取締役会は経験豊富であると考えられます ( 8年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/08/17 16:17
終値	2026/08/17 00:00
収益	2026/06/30
年間収益	2025/09/30

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Outlook Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。9

アナリスト	機関
Edward Woo	Ascendiant Capital Markets LLC
Brian Kemp Dolliver	Brookline Capital Markets
Kumaraguru Raja	Brookline Capital Markets

Outlook Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Independent Director recently bought €152k worth of stock

Insufficient new directors

Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026

Outlook Therapeutics, Inc., Annual General Meeting, Mar 10, 2026

Insufficient new directors

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Recent updates

Outlook Therapeutics, Inc. announced delayed 10-Q filing

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. to Report Q3, 2026 Results on Aug 14, 2026

Forecast to breakeven in 2028

Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet Amd

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. Regains Compliance with Minimum Bid Price Requirement

Outlook Therapeutics, Inc. Announces FDA Acceptance Of Resubmitted Biologics License Application For ONS-5010/LYTENAVA (Bevacizumab-Vikg) As A Treatment For Wet AMD

Independent Director recently bought €152k worth of stock

Outlook Therapeutics, Inc. Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process For ONS-5010/LYTENAVA (Bevacizumab-Vikg) And Plans To Resubmit BLA To FDA In June 2026

Insufficient new directors

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics Inc. Announces FDA Accepts Formal Dispute Resolution Request for ONS-5010/LYTENAVA (Bevacizumab-Vikg)

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. announced that it has received $18.36 million in funding from Atlas Sciences, LLC

Outlook Therapeutics, Inc. Announces Resignation of Dr. Julia Haller from the Board and Member of the Nominating and Corporate Governance Committee, Effective March 11, 2026

Outlook Therapeutics Provides Update Following Type A Meeting With FDA Regarding ONS-5010/LYTENAVA (Bevacizumab-Vikg)

Outlook Therapeutics, Inc. Receives Notice of Potential Delisting Due to Low Stock Price on Nasdaq

Outlook Therapeutics, Inc. Submits Type A Meeting Request to FDA Following Complete Response Letter

Outlook Therapeutics, Inc., Annual General Meeting, Mar 10, 2026

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™ (Bevacizumab-Vikg) for the Treatment of Wet Amd

Insufficient new directors

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. Re-Submits Biologics License Application for ONS-5010

Outlook Therapeutics, Inc. Announces Type A Meeting with the U.S. Food and Drug Administration Resubmission for Ons-5010

Outlook Therapeutics, Inc. Provides Regulatory Update on U.S. Food and Drug Administration Review of Ons-5010/Lytenava™? (Bevacizumab-Vikg) for the Treatment of Wet Amd

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc.(NasdaqCM:OTLK) dropped from Russell 2000 Index

Outlook Therapeutics®? Announces Smc Recommendation of Lytenava™ (Bevacizumab Grapa) for the Treatment of Wet Amd

Outlook Therapeutics, Inc. Announces Commercial Launch of LYTENAVA (bevacizumab G gamma) in Germany and the UK for the Treatment of Wet AMD

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $13 million.

Outlook Therapeutics, Inc. has filed a Follow-on Equity Offering.

Outlook Therapeutics, Inc. Announces U.S. Food and Drug Administration Resubmission of ONS-5010 Biologics License Application

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics, Inc., Annual General Meeting, Mar 11, 2025

Outlook Therapeutics, Inc. Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from Norse Eight Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Outlook Therapeutics, Inc. Announces Complete Twelve Week Efficacy and Safety Results of Northeast EIGHT Clinical Trial

Outlook Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt

Outlook Therapeutics, Inc. Streamlines Operations

Outlook Therapeutics, Inc. Announces Chief Executive Officer Changes

Outlook Therapeutics, Inc Announces Resignation of Russell Trenary as President

Outlook Therapeutics, Inc. Announces Preliminary Topline Results of Norse Eight Clinical Trial

Forecast to breakeven in 2027

Outlook Therapeutics Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

New major risk - Financial position

Outlook Therapeutics, Inc. to Report Q3, 2024 Results on Aug 14, 2024

Insufficient new directors

Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD

Outlook Therapeutics, Inc. to Report Q2, 2024 Results on May 16, 2024

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

New major risk - Shareholder dilution

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

マネジメント基準チェック /24